MWNA
FDMT icon

Marshall Wace North America’s 4D Molecular Therapeutics FDMT Stock Holding History

Marshall Wace North America’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-35,825
Closed -$1.49M – 1586
2020
Q4 		$1.49M Buy
+35,825
New +$1.48M 0.01% 833

Other funds holding FDMT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return

Marshall Wace North America's FDMT Position: Q1 2021 in Review

Marshall Wace North America sold out of 4D Molecular Therapeutics (FDMT) in Q1 2021, closing a stake of 35,825 shares — an estimated $1.49M sold.

Marshall Wace North America first reported a position in FDMT in Q4 2020 and held it in 1 quarter. The position peaked at $1.49M in Q4 2020. 64 funds tracked by Wall St. Rank hold FDMT as of Q1 2021.

  • Marshall Wace North America reported no remaining 4D Molecular Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Marshall Wace North America sold 35,825 4D Molecular Therapeutics shares in Q1 2021, an estimated $1.49M.
  • Marshall Wace North America first reported a position in 4D Molecular Therapeutics in Q4 2020 and held it in 1 quarter.
  • Marshall Wace North America's 4D Molecular Therapeutics position peaked at $1.49M in Q4 2020.
  • 64 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2021.

Based on Marshall Wace North America's 13F filing for Q1 2021, filed 17 May 2021.